share_log

Replimune To Present At ASCO Jun. 5-6

Benzinga Real-time News ·  May 27, 2022 05:20

WOBURN, Mass., May 26, 2022 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ:REPL), a clinical stage biotechnology company pioneering the development of a novel class of tumor-directed oncolytic immunotherapies, today announced multiple presentations at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting being held in Chicago, IL from June 3 to June 7, 2022.

Details for the presentations are as follows:

Data presentation

Updated results from the skin cancer cohorts from an ongoing Phase 1/2 multi-cohort study of RP1, an enhanced potency oncolytic HSV, combined with nivolumab (IGNYTE)

  • Session Title: Melanoma/Skin Cancers
  • Session Date and Time: Monday, June 6, 2022, 1:15 PM-4:15 PM CDT
  • Location: McCormick Place, Exhibit Hall A, Poster 146
  • Abstract: 9553

Trial in progress presentations

A randomized, controlled, open-label, phase 2 study of cemiplimab ± RP1 in patients with advanced cutaneous squamous cell carcinoma (CERPASS)

  • Session Title: Melanoma/Skin Cancers
  • Session Date and Time: Monday, June 6, 2022, 1:15 PM-4:15 PM CDT
  • Location: McCormick Place, Exhibit Hall A, Poster 184a
  • Abstract: TPS9593

An open-label, multicenter, phase 1b/2 study of RP1, a first-in-class, enhanced potency oncolytic virus in solid organ transplant recipients with advanced cutaneous malignancies (ARTACUS)

  • Session Title: Melanoma/Skin Cancers
  • Session Date and Time: Monday, June 6, 2022, 1:15 PM-4:15 PM CDT
  • Location: McCormick Place, Exhibit Hall A, Poster 187a
  • Abstract: TPS9597

A phase 1 trial of RP2, a first-in-class, enhanced potency oncolytic HSV expressing an anti-CTLA-4 antibody as a single agent and combined with nivolumab in patients with advanced solid tumors

  • Session Title: Developmental Therapeutics Immunotherapy
  • Session Date and Time: Sunday, June 5, 2022, 8:00 AM-11:00 AM CDT
  • Location: McCormick Place, Exhibit Hall A, Poster 339b
  • Abstract: TPS2704

An open-label, multicenter, phase 1 study of RP3 as a single agent and in combination with nivolumab in patients (pts) with solid tumors

  • Session Title: Developmental Therapeutics Immunotherapy
  • Session Date and Time: Sunday, June 5, 2022, 8:00 AM-11:00 AM CDT
  • Location: McCormick Place, Exhibit Hall A, Poster 340a
  • Abstract: TPS2705
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment